National Clinical Research, Inc.

09/10/2025

Have you ever wondered: Why join a clinical trial?

✨It’s more than just participation—it’s impact.

💵 Compensation may be available for your time

🧪 You may access cutting-edge treatments before they’re widely available

👥 Be part of something bigger than yourself

Fill out an interest form today at ncrinc.net!

https://ncrinc.net/complete-interest-form/

Complete Interest Form If you are human, leave this field blank.Name *AddressApt, suite, etc.CountryCityStateZip codeEmail *PhoneIs this a cell phone number?YesNoOK to text?YesNoDisclaimer:By providing my phone number to “National Clinical Research”, I agree and acknowledge that “National Clin...

02/10/2025

Noticed memory changes in the past year?

🩺The Alzheimer's Research Center at NCR is conducting a memory loss pre-screening study

🧠Study includes a no-cost memory test & pTAU blood screen

📍 Located in Richmond, VA

02/09/2025

🩺Doctors at NCR are conducting a study for individuals with high blood pressure who also carry excess weight.

💊 You may qualify for this hypertension GLP-1 trial sponsored by !

📋 Fill out an interest form on our website or call us to get involved!

🔗Learn More: https://ncrinc.net/resistant-hypertension/

02/09/2025

At National Clinical Research, we’re committed to developing tomorrow’s medications today!

Curious about our research? Tap the link in our bio or visit ncrinc.net to learn more!

20/05/2025

National Clinical Research recognizes the essential role of clinical trials and their promise in advancing better therapies for today’s patients and those of the future.

11/07/2024

From our Chief Medical Officer John K. Scott:

"We are excited to announce the recent approval of . It’s times like these that raise our hopes toward the eventual development of a treatment to end human suffering from such a condition.

As we continue to expand on the current knowledge and disease target mechanisms, we expect to slow the rate of memory decline until there is no further progression. Coupled with earlier screening and detection methods, the ability to help patients in the earliest stages maintain their quality of life, independence, and lessen the caregiver burden so that they also may lead productive lives no longer sounds like impossible science fiction.

National Clinical Research, Inc. has contributed significantly to ’s disease clinical research and we plan to continue conducting quality studies until the above vision has been achieved.

We could not enjoy the rewards of our efforts today without an exceptional team of coordinators, recruiters, raters, managers, greeters, mixers, phlebotomists, and physicians. Thank you for your continued tenacious spirit, integrity and compassion in this work.

We also have to thank the hundreds of patient volunteers who come to our clinic seeking help and willing to take a leap into the unknown world of . They have put their confidence in us to provide opportunities that may benefit not only themselves but the greater community. Our patients are the true trailblazers for which donanemab has proven successful."

; 's

The Investor Relations website contains information about Eli Lilly and Company's business for stockholders, potential investors, and financial analysts.

17/06/2024

Doctors at National Clinical Research are conducting a research study for 6-17 year olds who have migraines. Compensation is provided for time and travel. To learn more contact us at 804-755-2300.

14/03/2024

Happy to announce our patient care representative, Denise Pauley, is the Event Experience Chair for the 2024 Walk to End Alzheimer's in November. https://www.facebook.com/share/p/xKi8fCF9o1ikoLsF/?mibextid=WC7FNe

Thank you Denise Pauley for saying yes to being our 2024 Walk to End Alzheimer's Event Experience chair! New to RVA, Denise jumped right into the Walk to End Alzheimer's in 2023. With a history of event planning we're thrilled for her leadership to make the 2024 Walk to End Alzheimer's truly special at our new location, City Stadium! The Walk is powerful and an amazing way for the Alzheimer's Association to spread awareness to the communities we serve.

29/02/2024

Doctors at National Clinical Research, Inc. are conducting a research study for 6-17 year olds who suffer from migraines. Compensation is available for participation. Contact us at 804-755-2300 to learn more.

09/08/2023

NovoNordisk announced that that their drug, Semaglutide 2.4 mg, reduces the risk of major adverse cardiovascular events by 20% in adults with overweight or obesity in the SELECT trial.
NCR was honored to play a role in SELECT as one of 800 research sites in 41 countries that enrolled over 17,000 patients in the world.

If you are interested in learning more check out the news release:
https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=166301

As always, we thank our volunteers for their contribution during this trial.

Our medicines are for the approved indication for which they are authorised in the local country or region. For more information, please visit our product page

20/07/2023

🎉 Exciting News! 🎉
We are proud to share our Alzheimer’s Research Center played a vital role in evaluating Lecanemab which just recently received a full FDA approval and became the first-ever medication that can substantially reduce the cognitive and functional decline from Alzheimer's disease! This groundbreaking achievement gives us all hope and will lead us to even better treatments for this disease in the future. Thank you to our amazing team, study participants, doctors and neurologist in the community who referred patients to us, and local outsourced vendors for making this possible. Together, we are making a difference in the fight against Alzheimer's! 🌟

27/02/2023

Doctors at National Clinical Research, Inc. are conducting a Baby Formula study. Interested? Want to learn more? Call us at 804-755-2300 or visit www.ncrinc.net

Developing Tomorrow's Medications Today